Announced
Completed
Financials
Tags
experimental drugs
United States
Pharmaceuticals
therapeutics
Acquisition
Majority
Domestic
Friendly
Single Bidder
Public
Completed
Synopsis
Biogen, a biotechnology company, completed the acquisition of Reata Pharmaceuticals, a biopharmaceutical company, for $7.3bn. “By adding a highly complementary product in an area of significant unmet medical need to our portfolio, we believe the acquisition of Reata aligns with our strategy to serve patients, drive sustainable growth and create significant shareholder value. With the transaction now complete, we look forward to leveraging Biogen’s rare disease expertise and capabilities to work together with our Reata colleagues as one team to bring SKYCLARYS® to patients living with this devastating disease," Christopher A. Viehbacher, Biogen President and CEO.
Search a database of more than 250,000 verified dealmakers
Receive automated updates on global transactions
Follow the activity, relationships and transactions of top dealmakers
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.